TTY BIOPHARM COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 77.3 TWD | +0.91% |
|
+1.71% | -3.86% |
| Mar. 14 | TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 08 | TTY Biopharm Company Limited Announces Change of CFO and Financial Officer | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 20,489 | 17,057 | 17,107 | 20,737 | 19,991 | 19,221 | - |
| Enterprise Value (EV) 1 | 19,644 | 16,961 | 16,600 | 20,737 | 19,991 | 19,221 | 19,221 |
| P/E ratio | 22.8 x | 18.5 x | 20.6 x | 19 x | 17.7 x | 14.3 x | 11.6 x |
| Yield | 4.85% | 5.83% | 4.36% | 4.08% | 4.35% | - | - |
| Capitalization / Revenue | 4.59 x | 4.04 x | 3.77 x | 4.1 x | 3.63 x | 3.32 x | 3.05 x |
| EV / Revenue | 4.59 x | 4.04 x | 3.77 x | 4.1 x | 3.63 x | 3.32 x | 3.05 x |
| EV / EBITDA | 14.8 x | 15.3 x | 13.1 x | 14.7 x | 12.7 x | 10.3 x | 9.6 x |
| EV / FCF | 17.6 x | 47.6 x | 14.3 x | 18.1 x | 19.7 x | 17.5 x | - |
| FCF Yield | 5.67% | 2.1% | 6.99% | 5.52% | 5.07% | 5.71% | - |
| Price to Book | 3.68 x | 3.13 x | 3.31 x | 3.66 x | 3.36 x | 2.95 x | - |
| Nbr of stocks (in thousands) | 248,650 | 248,650 | 248,650 | 248,650 | 248,650 | 248,650 | - |
| Reference price 2 | 82.40 | 68.60 | 68.80 | 83.40 | 80.40 | 77.30 | 77.30 |
| Announcement Date | 3/15/20 | 3/19/21 | 3/9/22 | 3/14/23 | 3/14/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,466 | 4,222 | 4,536 | 5,062 | 5,506 | 5,798 | 6,303 |
| EBITDA 1 | 1,381 | 1,114 | 1,308 | 1,414 | 1,573 | 1,872 | 2,003 |
| EBIT 1 | 1,229 | 957.4 | 1,141 | 1,228 | 1,372 | 1,616 | 1,918 |
| Operating Margin | 27.51% | 22.68% | 25.15% | 24.26% | 24.93% | 27.88% | 30.43% |
| Earnings before Tax (EBT) 1 | 1,203 | 1,202 | 1,087 | 1,408 | 1,419 | 1,706 | 2,122 |
| Net income 1 | 900.1 | 924.2 | 831.9 | 1,094 | 1,129 | 1,346 | 1,659 |
| Net margin | 20.15% | 21.89% | 18.34% | 21.62% | 20.5% | 23.22% | 26.32% |
| EPS 2 | 3.610 | 3.710 | 3.340 | 4.400 | 4.530 | 5.415 | 6.670 |
| Free Cash Flow 1 | 1,162 | 358.2 | 1,196 | 1,144 | 1,014 | 1,097 | - |
| FCF margin | 26.01% | 8.49% | 26.37% | 22.61% | 18.42% | 18.92% | - |
| FCF Conversion (EBITDA) | 84.12% | 32.15% | 91.44% | 80.91% | 64.45% | 58.6% | - |
| FCF Conversion (Net income) | 129.06% | 38.76% | 143.77% | 104.55% | 89.85% | 81.47% | - |
| Dividend per Share | 4.000 | 4.000 | 3.000 | 3.400 | 3.500 | - | - |
| Announcement Date | 3/15/20 | 3/19/21 | 3/9/22 | 3/14/23 | 3/14/24 | - | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,060 | 1,468 | 1,037 | 1,166 | 1,326 | 1,533 | 1,166 | 1,262 | 1,433 | 1,645 | 1,234 | 1,353 | 1,563 | 1,796 | 1,306 |
| EBITDA | 314.9 | 420.3 | 291.6 | 343 | 414.5 | 365.2 | 295.4 | - | - | - | - | - | - | - | - |
| EBIT 1 | 272.7 | 376.8 | 246.6 | 297.7 | 369 | 314.7 | 245.4 | 334 | 504.4 | 288.6 | 275 | 365 | 512 | 557 | 302 |
| Operating Margin | 25.72% | 25.66% | 23.77% | 25.54% | 27.83% | 20.53% | 21.04% | 26.47% | 35.2% | 17.55% | 22.29% | 26.98% | 32.76% | 31.01% | 23.12% |
| Earnings before Tax (EBT) 1 | 314.2 | 425.6 | 287.2 | 351 | 437 | 333.1 | 293.3 | 393.4 | 505.7 | 227 | 325 | 402 | 568 | 593 | 337 |
| Net income 1 | 253.4 | 343.5 | 227.5 | 284.2 | 338 | 244.7 | 238.7 | 308.7 | 376.3 | 204.8 | 257 | 316 | 449 | 452 | 271 |
| Net margin | 23.9% | 23.39% | 21.94% | 24.38% | 25.49% | 15.96% | 20.46% | 24.47% | 26.26% | 12.45% | 20.83% | 23.36% | 28.73% | 25.17% | 20.75% |
| EPS 2 | 1.020 | 1.380 | 0.9100 | 1.140 | 1.360 | 0.9900 | 0.9600 | 1.240 | 1.510 | 0.8200 | 1.030 | 1.270 | 1.810 | 1.820 | 1.090 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/9/22 | 5/13/22 | 8/5/22 | 11/4/22 | 3/14/23 | 5/11/23 | 8/10/23 | 11/3/23 | 3/14/24 | - | - | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | 845 | 96.6 | 507 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 1,162 | 358 | 1,196 | 1,144 | 1,014 | 1,097 | - |
| ROE (net income / shareholders' equity) | 15.8% | 16.8% | 15.7% | 20.2% | 19.5% | 19.2% | 20.8% |
| ROA (Net income/ Total Assets) | 9.68% | 9.77% | 8.92% | 11.6% | 11.6% | 12.8% | 13.6% |
| Assets 1 | 9,303 | 9,457 | 9,329 | 9,449 | 9,738 | 10,515 | 12,190 |
| Book Value Per Share 2 | 22.40 | 21.90 | 20.80 | 22.80 | 23.90 | 26.20 | - |
| Cash Flow per Share | 4.860 | 2.110 | 5.040 | 4.970 | - | - | - |
| Capex 1 | 48.2 | 168 | 60.3 | 91.5 | 71.3 | 72 | 75 |
| Capex / Sales | 1.08% | 3.98% | 1.33% | 1.81% | 1.3% | 1.24% | 1.19% |
| Announcement Date | 3/15/20 | 3/19/21 | 3/9/22 | 3/14/23 | 3/14/24 | - | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
76.6
TWD
Average target price
86.5
TWD
Spread / Average Target
+12.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.86% | 584M | |
| +25.58% | 661B | |
| +26.74% | 566B | |
| -6.56% | 352B | |
| +19.60% | 332B | |
| +3.25% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -5.15% | 145B |
- Stock Market
- Equities
- 4105 Stock
- Financials TTY Biopharm Company Limited
